Literature DB >> 26542042

Urosepsis: Overview of the Diagnostic and Treatment Challenges.

Florian M E Wagenlehner1, Adrian Pilatz1, Wolfgang Weidner1, Kurt G Naber2.   

Abstract

Urosepsis is defined as sepsis caused by an infection in the urogenital tract. In approximately 30% of all septic patients the infectious focus is localized in the urogenital tract, mainly due to obstructions at various levels, such as ureteral stones. Urosepsis may also occur after operations in the urogenital tract. In urosepsis, complete bacteria and components of the bacterial cell wall from the urogenital tract trigger the host inflammatory event and act as exogenous pyrogens on eukaryotic target cells of patients. A burst of second messenger molecules leads to several different stages of the septic process, from hyperactivity to immunosuppression. As pyelonephritis is the most frequent cause for urosepsis, the kidney function is therefore most important in terms of cause and as a target organ for dysfunction in the course of the sepsis.Since effective antimicrobial therapy must be initiated early during sepsis, the empiric intravenous therapy should be initiated immediately after microbiological sampling. For the selection of appropriate antimicrobials, it is important to know risk factors for resistant organisms and whether the sepsis is primary or secondary and community or nosocomially acquired. In addition, the preceding antimicrobial therapies should be recorded as precisely as possible. Resistance surveillance should, in any case, be performed locally to adjust for the best suitable empiric treatment. Treatment challenges arise from the rapid increase of antibiotic resistance in Gram-negative bacteria, especially extended-spectrum β-lactamase (ESBL)-producing bacteria. Treatment of urosepsis comprises four basic strategies I) supportive therapy (stabilizing and maintaining blood pressure), II) antimicrobial therapy, III) control or elimination of the complicating factor, and IV) specific sepsis therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26542042     DOI: 10.1128/microbiolspec.UTI-0003-2012

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  15 in total

1.  The prognostic performance of Sepsis-3 and SIRS criteria for patients with urolithiasis-associated sepsis transferred to ICU following surgical interventions.

Authors:  Bowen Shi; Fei Shi; Ke Xu; Liuhui Shi; Haixiao Tang; Ning Wang; Yanyuan Wu; Jun Gu; Jie Ding; Yunteng Huang
Journal:  Exp Ther Med       Date:  2019-09-26       Impact factor: 2.447

2.  Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.

Authors:  Kamrul Islam; Fekade B Sime; Steven C Wallis; Michelle J Bauer; Saiyuri Naicker; Hayoung Won; Hosam M Zowawi; Md Abu Choudhury; Tahmina Shirin; Zakir H Habib; Patrick N A Harris; Meerjady S Flora; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2022-08-04       Impact factor: 5.938

3.  Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins.

Authors:  Milena Tocut; Iris Zohar; Orna Schwartz; Orit Yossepowitch; Yasmin Maor
Journal:  BMC Infect Dis       Date:  2022-06-24       Impact factor: 3.667

4.  Inflammation-Induced Adhesin-Receptor Interaction Provides a Fitness Advantage to Uropathogenic E. coli during Chronic Infection.

Authors:  Matt S Conover; Ségolène Ruer; Joemar Taganna; Vasilios Kalas; Henri De Greve; Jerome S Pinkner; Karen W Dodson; Han Remaut; Scott J Hultgren
Journal:  Cell Host Microbe       Date:  2016-09-22       Impact factor: 21.023

5.  [Urosepsis. Update on diagnosis and treatment].

Authors:  F M E Wagenlehner; J Alidjanov; A Pilatz
Journal:  Urologe A       Date:  2016-04       Impact factor: 0.639

6.  Reduced utility of early procalcitonin and blood culture determination in patients with febrile urinary tract infections in the emergency department.

Authors:  Marcello Covino; Alberto Manno; Giuseppe Merra; Benedetta Simeoni; Andrea Piccioni; Luigi Carbone; Evelina Forte; Veronica Ojetti; Francesco Franceschi; Rita Murri
Journal:  Intern Emerg Med       Date:  2019-10-24       Impact factor: 3.397

7.  Urosepsis and the urologist!

Authors:  James Ryan; Eoghan O'Neill; Liza McLornan
Journal:  Curr Urol       Date:  2021-03-29

8.  A new point-of-care test for the rapid detection of urinary tract infections.

Authors:  Alyexandra Arienzo; Valentina Cellitti; Valeria Ferrante; Francesca Losito; Ottavia Stalio; Lorenza Murgia; Rossella Marino; Flavia Cristofano; Michela Orrù; Paolo Visca; Salvatore Di Somma; Lorena Silvestri; Vincenzo Ziparo; Giovanni Antonini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-09       Impact factor: 3.267

9.  Development and validation of a risk-prediction nomogram for patients with ureteral calculi associated with urosepsis: A retrospective analysis.

Authors:  Ming Hu; Xintai Zhong; Xuejiang Cui; Xun Xu; Zhanying Zhang; Lixian Guan; Quanyao Feng; Yiheng Huang; Weilie Hu
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

Review 10.  Prevention and management of urosepsis triggered by ureteroscopy.

Authors:  Kymora B Scotland; Dirk Lange
Journal:  Res Rep Urol       Date:  2018-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.